三诺生物：公司董事会决定不向下修正“三诺转债”转股价格

Core Viewpoint - Sanofi Bio (300298) has decided not to adjust the conversion price of "Sanofi Convertible Bonds" based on confidence in the company's long-term development potential and intrinsic value, aiming to protect the overall and long-term interests of all shareholders and creditors [1] Group 1 - The decision not to revise the conversion price is influenced by multiple factors, including the company's operational reality, market environment, and stock price trends [1] - The company emphasizes its commitment to improving operational management efficiency and promoting sustainable high-quality development [1] - The board's decision aims to clarify investor expectations and strengthen the foundation for bond conversion [1]